Advertisement

Topics

Eisai Corporation of North America Company Profile

00:46 EST 23rd November 2017 | BioPortfolio

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.


News Articles [886 Associated News Articles listed on BioPortfolio]

Eisai, Biotoscana ink exclusive licensing pact for Latin America

Eisai announced that its US subsidiary, Eisai, has signed an exclusive licensing agreement with Grupo Biotoscana for Eisai's oncology and neurology products in Latin America.

Eisai and Biotoscana Sign Exclusive Licensing Agreement for Latin America

TOKYO, Oct 4, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary, Eisai Inc., has signed an exclusive licensing agreement with Grupo Biotoscana for Eisai's oncology an...

Eisai enters license deals for Latin America and Japan

Eisai’s US subsidiary has signed an exclusive licensing agreement with Uruguay-headquartered Grupo…

Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December

Following Agreement with National Association of Statutory Health Insurance Funds TOKYO, Nov 20, 2017 - (JCN Newswire) - Eisai Co., Ltd. has announced that its German sales company Eisai GmbH (Loca...

Ono and Eisai focus on hepatocellular carcinoma in new trial collaboration

Eisai Co. Ltd. partnered with Ono Pharmaceutical Co. Ltd. to develop a hepatocellular carcinoma therapy combining Eisai’s Lenvima (lenvatinib) with Ono’s Opdivo (nivolumab).

Savaria Announces Resignation of Director and Appointment of New Director

LAVAL, QUEBEC -- (Marketwired) -- 07/07/17 -- Savaria Corporation (TSX: SIS) ("Savaria" or the "Corporation"), one of North America's leaders in the accessibility industry, is pleased to announce th...

FDA Approves Additional Use of Antiepileptic Drug Fycompa as Monotherapy for Partial-onset Seizures

July 27, 2017 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that on July 26, 2017 (U.S. time), its U.S. subsidiary Eisai Inc. received approval from the U.S. Food...

Biogen and Eisai Expand Collaboration for Development of Aducanumab in Alzheimer’s Disease

CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, Un...

PubMed Articles [1399 Associated PubMed Articles listed on BioPortfolio]

Historical and future trends in global source-receptor relationships of mercury.

Growing concern about the risk associated with increasing environmental mercury (Hg) concentrations has resulted in a focus on the relationships between intercontinental emitted and accumulated Hg. We...

The Paleo-Indian Entry into South America According to Mitogenomes.

Recent and compelling archaeological evidence attests to human presence ∼14.5 thousand years ago (Kya) at multiple sites in South America and a very early exploitation of extreme high-altitude Andea...

Second malignant neoplasms after childhood non-central nervous system embryonal tumours in North America: A population-based study.

Few studies in North America have quantified the risks of second malignant neoplasms (SMNs) among survivors of childhood non-central nervous system (non-CNS) embryonal tumours due to their rarity. We ...

Transoral thyroidectomy and parathyroidectomy - A North American series of robotic and endoscopic transoral approaches to the central neck.

Most thyroid surgery in North America is completed via a cervical incision, which leaves a permanent scar. Approaches without cutaneous incisions offer aesthetic advantages. This series represents the...

North American matsutake: names clarified and a new species described.

Tricholoma matsutake, known widely as "matsutake," has great commercial and cultural significance in Japan. Because Japanese production is insufficient to meet the high domestic demand, morphologicall...

Clinical Trials [482 Associated Clinical Trials listed on BioPortfolio]

Sorafenib-RT in Treating Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The incidence is highest in Asia and it is increasing in North America, with a two to three fold increase in mor...

Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin

This trial will be conducted in Africa, Asia, North America and South America. The aim of this clinical trial is to compare NN1250 with sitagliptin, as add-on to subject's own current oral...

Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes

This trial was conducted in Europe, Middle East, North America and South America. The aim of this trial was to compare the use of an intensified insulin treatment Insulin Aspart (NovoRapi...

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

This trial is conducted in Europe, North America and South America. The aim of this trial is to investigate the clinical efficacy of NNC0109-0012, a human monoclonal antibody, compared to ...

CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography

CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following...

Companies [1992 Associated Companies listed on BioPortfolio]

Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Res...

Eisai GmbH

Auf dem globalen Pharmamarkt zählt Eisai zu den führenden forschungs- orientierten Pharmaunternehmen. Mit innovativen Präparaten für Erkrankungen des Zentralen Nerven- systems sowie im Magen-Darm-...

Eisai Europe Ltd

Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of AEDs is a major strategic ar...

Eisai Europe Limited

Eisai is committed to making further contributions to addressing the diversified needs and improving quality of life of patients with epilepsy. Eisai has three currently marketed treatments in Eur...

Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facili...

More Information about "Eisai Corporation of North America" on BioPortfolio

We have published hundreds of Eisai Corporation of North America news stories on BioPortfolio along with dozens of Eisai Corporation of North America Clinical Trials and PubMed Articles about Eisai Corporation of North America for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eisai Corporation of North America Companies in our database. You can also find out about relevant Eisai Corporation of North America Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record